Drug Trial Radar · NCT05635708
A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer
Last checked: Nov 19, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
418
Actual
Start
Feb 10, 2023
Primary completion
Dec 19, 2025
Study completion Oct 29, 2026
Sponsor
- Lead sponsor
- BeiGeneBeOne Medicines (BeiGene) (ONC)
- Sponsor type
- Industry
- First posted
- Dec 2, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the antitumor activity, safety, and tolerability of tislelizumab plus investigational agent(s) with or without chemotherapy. This study is structured as a master protocol with separate sub- studies. Sub-study 1 includes participants with non-small cell lung cancer (NSCLC) with high programmed cell death protein ligand-1 (PD-L1) expression (≥ 50%), and Sub-study 2 includes participants with NSCLC with low or negative (PD-L1) expression (\< 50%).
Conditions
- Non-small Cell Lung Cancer
- Metastatic Non-small Cell Lung Cancer
Interventions
TislelizumabDrug
Administered by intravenous infusion
BGB-A445Drug
Administered by intravenous infusion
LBL-007Drug
Administered by intravenous infusion
CarboplatinDrug
Investigator's choice; administered by intravenous infusion
CisplatinDrug
Investigator's choice; administered by intravenous infusion
pemetrexedDrug
Investigator's choice; administered by intravenous infusion
PaclitaxelDrug
Investigator's choice; administered by intravenous infusion
Nab paclitaxelDrug
Investigator's choice; administered by intravenous infusion
BGB-15025Drug
Administered Orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Confirmed overall response rate (ORR)Time frame: Up to 6 months
Locations
61 sites in 15 countries. Site status is shown where the registry gives one.
Valkyrie Clinical Trials
Los Angeles, California
Massachusetts General Hospital
Boston, Massachusetts
Memorial Sloan Kettering Cancer Center Mskcc
New York, New York
Providence Portland Medical Center
Portland, Oregon
The University of Texas Md Anderson Cancer Center
Houston, Texas
Blacktown Cancer and Haematology Centre
Blacktown, New South Wales, Australia
Chris Obrien Lifehouse
Camperdown, New South Wales, Australia
Northern Beaches Hospital
Frenchs Forest, New South Wales, Australia
Port Macquarie Base Hospital
Port Macquarie, New South Wales, Australia
One Clinical Research
Nedlands, Western Australia, Australia
St John of God Health Care
Subiaco, Western Australia, Australia
Hospital de Amor Barretos
Barretos, Brazil
Hospital Do Cancer de Londrina
Londrina, Brazil
Centro Gaucho Integrado de Oncologia Hospital Mae de Deus
Porto Alegre, Brazil
Fundacao Faculdade Regional de Medicina de Sao Jose Do Rio Preto
São José do Rio Preto, Brazil
Icesp Instituto Do Cancer Do Estado de Sao Paulo Octavio Frias de Oliveira
São Paulo, Brazil
Cross Cancer Institute
Edmonton, Alberta, Canada
The Second Hospital of Anhui Medical University
Hefei, Anhui, China
The Fifth Medical Center of Chinese Pla General Hospital
Beijing, Beijing Municipality, China
Fujian Cancer Hospital
Fuzhou, Fujian, China
Affiliated Hospital of Hebei University
Baoding, Hebei, China
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China
Henan Cancer Hospital
Zhengzhou, Henan, China
Hubei Cancer Hospital
Wuhan, Hubei, China
Nantong Tumor Hospital Branch North
Nantong, Jiangsu, China
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China
The First Affiliated Hospital of Nanchang University Branch Xianghu
Nanchang, Jiangxi, China
Jining No1 Peoples Hospital East Branch
Jining, Shandong, China
Linyi Peoples Hospital
Linyi, Shandong, China
Affiliated Zhongshan Hospital of Fudan University
Shanghai, Shanghai Municipality, China
Shanghai East Hospital Branch Hospital
Shanghai, Shanghai Municipality, China
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, China
Shanxi Provincial Cancer Hospital
Taiyuan, Shanxi, China
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, China
Taizhou Hospital of Zhejiang
Taizhou, Zhejiang, China
Institut Curie
Paris, France
Chu Nantes Hopital Nord Laennec
SaintHerblain, France
Arensia Exploratory Medicine Llc
Tbilisi, Georgia
Regina Elena, Istituto Nazionale Dei Tumori, Ifo, Irccs
Roma, Italy
Centro Ricerche Cliniche Di Verona
Verona, Italy
Showing 40 of 61 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.